Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Miroslav Boudný"'
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Eva Ondroušková, Michaela Bohúnová, Kristýna Závacká, Patrik Čech, Petra Šmuhařová, Miroslav Boudný, Martina Oršulová, Anna Panovská, Lenka Radová, Michael Doubek, Karla Plevová, Marie Jarošová
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM, is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups with diver
Externí odkaz:
https://doaj.org/article/9874afffb5374bcba126ff413f2cbae2
Autor:
Prashant Khirsariya, Patrik Pospíšil, Lukáš Maier, Miroslav Boudný, Martin Babáš, Ondřej Kroutil, Marek Mráz, Robert Vácha, Kamil Paruch
Publikováno v:
Journal of Medicinal Chemistry. 65:5701-5723
Histone methyltransferase DOT1L is an attractive therapeutic target for the treatment of hematological malignancies. Here, we report the design, synthesis, and profiling of new DOT1L inhibitors based on nonroutine carbocyclic C-nucleoside scaffolds.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2152f907f5d5926092df7f38da36721b
https://doi.org/10.1021/acs.jmedchem.1c02228
https://doi.org/10.1021/acs.jmedchem.1c02228